Hims & Hers Health Q1 2025: Unraveling Contradictions in Weight Loss Guidance and GLP-1 Strategies

Weight loss revenue guidance and category growth, role of personalization in weight loss category, importance of personalization for weight loss category, GLP-1 revenue contribution, and GLP-1 personalization and transition to commercial doses are the key contradictions discussed in Hims & Hers Health's latest 2025Q1 earnings call.



Revenue Growth and Personalization Expansion:
- Hims & Hers Health reported revenue of $586 million for Q1 2025, which more than doubled year-over-year.
- The growth was driven by strong execution on strategies to provide personalized solutions, increasing the subscriber base to nearly 2.4 million, with over 1.4 million subscribers using personalized solutions.

Earnings and Adjusted EBITDA Increase:
- The company's adjusted EBITDA nearly tripled, reaching $91 million, compared to the same quarter last year.
- This increase was due to operational leverage from investments in platform infrastructure and improved marketing efficiency.

Weight Loss Specialty and Partnerships:
- The weight loss specialty has become one of Hims & Hers' largest, with plans to expand access to branded Wegovy.
- This expansion is a result of strategic partnerships, including the collaboration with Novo Nordisk, which aims to reach more customers and provide broader brand choices.

Sexual Health Transformation:
- Over 40% of sexual health subscribers now utilize daily offerings, marking a significant shift from less than 10% two years ago.
- This reflects a transition towards a more personalized and comprehensive care model, improving retention and driving long-term growth.